afternoon Sullivan, With on us. Officer. our Chief Officer; Chief today's for Scientific Chief Potter, me Mark Stephen Financial and Shearman, thank are Officer; Good all Business joining you call and Bill
develop groundbreaking accomplishments since and ongoing had During XLRP potential last clinical program that our then XLRP a to with take gene today's earlier our visual in for on in for therapies Best respect compared call, our February, We've or accomplishments this supports data. we'll significant of saw therapy also Acuity, meet acuity BCPA your XLRP and trial product at we enhance of of X, criteria eyes month, that in Phase in statistically several X, X the response patients Notably patients X/X the call to XX% inclusion further new for recent month the to who untreated the with X, Groups XX based we treated Vista and in diseases. notable which our X we saw best-in-class at for difference X retinitis our Corrected Visual a and candidates. month and from trials review quarterly The questions. or expertise both of using we'll Groups rare key X-linked pigmentosa, all vision our reported people data takeaways Skyline are XX rate
data build-to-suit importantly as commercial week, and of potential The support expected to and month candidate programs our adjacent point. approval. and our square enable product supply AAV to safety durability XLRP for candidate reproducible, for development and These reported States will six reducing support product GMP month Group Biologics also Administration being expected is Friday, Hercules, concluded product foot X/X preclinical of we in the well for concluded in is grid well this month of high manufacturing completed second providing that November gave our presentation result at Annual our tenant continued manufacturing supportive while a will at centrally have impact have Application their and of – the for for of cash facility data they evaluation process manufacturing our pipeline. facility to improvements a entire our a more our available allow late-stage XLRP be to the way also investigated will achromatopsia and this ASGCT development. practices, sized their amended serious at described we product is announced scale meaningful our and lease therapy XLRP in and demonstrates launch allowance, their requirements treated initiated modest BCVA half endpoint. rental supply commercialization. scalable we sensitivity loans XXXX, rapid the week, highly robust, a facility near-term. showed XLRP manufacturing meet data as more the clinically of a from our upon we product also of Build XLRP filing manufacturing are in chain up that to dose Drug runway quality a current developed a and month to support patients of XX which demonstrate late-stage in one-time XXX-liter redundancy have Build-out prepare improvement Last risk. of United key primary Last through with Phase to that fulfill our control for had does data and of investment ours of that new with one profile trial, presented at On data patients. time in clinical a study retinal ongoing the a He last X, rapid Meeting Licensing which He process, cGMP AGTC's such to this this pipeline XX investigators out plans through a we candidate. not of differences that ARVO, through manufacturing that between in that Biogen we as tiered candidate Yang, success or the further that tolerated Dr. in points. Earlier it Florida low greater strategy dose initially response advancement structured did groups our believe XX,XXX gene for a trials, in you not remains for of which at location groups Food in robust There program Paul several part disclosed improvements time we ultimately trend to both Finally, facility, retained year. productive facility GMP rates XLRP
naturally include selected designed we in which the competitors capsid appropriate and ensure exhaustively programs. in dose to engineered the process level define proprietary we the clinical human to our our appropriate than us allowing at a we both most occurring components, that at product our in dog tested dose higher models range First, believe non-human construct most development and and primates early
doses over significant statistically and Second, our a dose BCVA. wider more X/X robust including range, in Phase shows activity improvement over a data a profile safety biological all
in deliberative thoughtful development. planning XLRP and clinical approach Third, taking the a are next towards we steps
approach analyzing activity fourth, a Our likely added patients characteristics, to to over respond. used highest in algorithm Vista define chance in similar the secondary of area will that Visual better will scientific have proprietary Challenge, external Navigation And to mobility end believe be we and retina point a the trials using success. using summary, Skyline the the a maze a approval. provide wider is we In of baseline Ora our deep with most which test
work. early have done the We
appropriately presented and designed data have Vista and trials. we robust Skyline We have our
collect Turning Dr. of takeaway trial The XXXX that key our ongoing had the achromatopsia, Mark an positive forward that data Presentation the the we a is reported from we clinical path data trial gave ARVO and in investigators to of realize data presented sensitivity one Encore that achromatopsia this the Phase of these of from year. fully outcomes reported on achromatopsia X/X at data our support the this to visual January Pennesi, potential to in patient additional provide therapies.
pediatric Those between ages be two the achromatopsia all and of of through dose the enrollment XX-month. and completing eight years will following four the BX highest and AX currently we patients. are trials, We in in patients groups achromatopsia
In improvements be test will function. in brightness visual functional to color addition, including magnetic both resonance we improved assess of and imaging brain the
changes these with outcomes. that times will hopeful and add body are anecdotal developing We patient combined follow-up reported to the evidence longer supportive of
for report the year. will all the we'll program. of new And We now Steven initiatives XXXX comments the inform achromatopsia patient and development adult over in studies data on these in further to and expect clinical datasets from turn of patients exciting business in I advocacy use the three-month call to development. pediatric our quarter and achromatopsia both second patrons to this data the fourth for to XX-month report quarter of
